15.1% Average Loss With Oral Semaglutide at 68 Weeks
OASIS 1 evaluated an oral semaglutide regimen escalated to 50 mg daily in adults without type 2 diabetes. The 68-week trial reported average weight loss under defined eligibility and lifestyle-intervention conditions. The studied 50 mg dose should not be treated as the same as the currently listed U.S. 25 mg oral maintenance dose.
At week 68, estimated mean body-weight change was −15.1% with oral semaglutide 50 mg and −2.4% with placebo.
At least 5% weight loss occurred in 85% of semaglutide participants and 26% of placebo participants. Gastrointestinal adverse events occurred in 80% and 46%, respectively, and were mostly mild to moderate. The study used a 50 mg daily regimen; it did not compare the currently listed U.S. 25 mg oral maintenance dose.
Turn the study result into a better program comparison
If this oral-semaglutide result prompts you to explore GLP-1 care, compare the practical details the study cannot answer: available medication forms, clinician access, product status, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 667 adults without type 2 diabetes who had obesity, or overweight plus a weight-related complication
- Follow-up
- 68 weeks
- Treatment comparison
- Oral semaglutide escalated to 50 mg once daily compared with matching placebo, with lifestyle intervention
- Study design
- Phase 3, multicenter, double-blind, randomized, placebo-controlled superiority trial
A study result is not a personal treatment plan
This was a study of a 50 mg daily oral regimen, not a provider comparison and not a finding that any online program offers that studied dose. Current labeled products, available tablet strengths, prescription suitability, insurance terms, and dose progression should be reviewed with a licensed clinician and current prescribing information.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The trial lasted 68 weeks and does not establish durability of weight change or safety after treatment discontinuation.
- Adults with type 2 diabetes were excluded, so the findings do not directly apply to that population.
- The trial compared the 50 mg regimen with placebo rather than another active obesity treatment or the currently listed U.S. 25 mg oral maintenance dose.
- The sample size and follow-up were not designed to reliably characterize rare or longer-latency harms.
- The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at The Lancet